Annual Accounts Payable
$4.53 M
+$2.95 M+186.77%
December 31, 2023
Summary
- As of February 7, 2025, PLRX annual accounts payable is $4.53 million, with the most recent change of +$2.95 million (+186.77%) on December 31, 2023.
- During the last 3 years, PLRX annual accounts payable has risen by +$2.51 million (+123.97%).
- PLRX annual accounts payable is now at all-time high.
Performance
PLRX Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$6.89 M
+$3.64 M+112.20%
September 30, 2024
Summary
- As of February 7, 2025, PLRX quarterly accounts payable is $6.89 million, with the most recent change of +$3.64 million (+112.20%) on September 30, 2024.
- Over the past year, PLRX quarterly accounts payable has increased by +$3.64 million (+112.20%).
- PLRX quarterly accounts payable is now -33.25% below its all-time high of $10.32 million, reached on June 30, 2019.
Performance
PLRX Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
PLRX Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +186.8% | +112.2% |
| 3 y3 years | +124.0% | +112.2% |
| 5 y5 years | +75.9% | +451.2% |
PLRX Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +186.8% | -6.0% | +385.6% |
| 5 y | 5-year | at high | +262.5% | -6.0% | +451.2% |
| alltime | all time | at high | +262.5% | -33.3% | +451.2% |
Pliant Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $6.89 M(+112.2%) |
| Jun 2024 | - | $3.25 M(-55.7%) |
| Mar 2024 | - | $7.33 M(+61.7%) |
| Dec 2023 | $4.53 M(+186.8%) | $4.53 M(+34.9%) |
| Sep 2023 | - | $3.36 M(+45.5%) |
| Jun 2023 | - | $2.31 M(+62.8%) |
| Mar 2023 | - | $1.42 M(-10.2%) |
| Dec 2022 | $1.58 M(-46.8%) | $1.58 M(-50.7%) |
| Sep 2022 | - | $3.21 M(+2.9%) |
| Jun 2022 | - | $3.12 M(-33.5%) |
| Mar 2022 | - | $4.68 M(+57.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2021 | $2.97 M(+46.9%) | $2.97 M(+14.0%) |
| Sep 2021 | - | $2.60 M(-5.8%) |
| Jun 2021 | - | $2.76 M(-4.2%) |
| Mar 2021 | - | $2.89 M(+42.7%) |
| Dec 2020 | $2.02 M(+61.8%) | $2.02 M(-35.6%) |
| Sep 2020 | - | $3.14 M(+26.5%) |
| Jun 2020 | - | $2.48 M(-1.9%) |
| Mar 2020 | - | $2.53 M(+102.6%) |
| Dec 2019 | $1.25 M(-51.5%) | $1.25 M(-87.9%) |
| Jun 2019 | - | $10.32 M(+141.2%) |
| Dec 2018 | $2.58 M | - |
| Dec 2018 | - | $4.28 M |
FAQ
- What is Pliant Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Pliant Therapeutics?
- What is Pliant Therapeutics annual accounts payable year-on-year change?
- What is Pliant Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Pliant Therapeutics?
- What is Pliant Therapeutics quarterly accounts payable year-on-year change?
What is Pliant Therapeutics annual accounts payable?
The current annual accounts payable of PLRX is $4.53 M
What is the all time high annual accounts payable for Pliant Therapeutics?
Pliant Therapeutics all-time high annual accounts payable is $4.53 M
What is Pliant Therapeutics annual accounts payable year-on-year change?
Over the past year, PLRX annual accounts payable has changed by +$2.95 M (+186.77%)
What is Pliant Therapeutics quarterly accounts payable?
The current quarterly accounts payable of PLRX is $6.89 M
What is the all time high quarterly accounts payable for Pliant Therapeutics?
Pliant Therapeutics all-time high quarterly accounts payable is $10.32 M
What is Pliant Therapeutics quarterly accounts payable year-on-year change?
Over the past year, PLRX quarterly accounts payable has changed by +$3.64 M (+112.20%)